The Journal of the American College of Cardiology Publishes Data for Gadavist® (gadobutrol) Showing High Diagnostic Accuracy for Coronary Artery Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--The Journal of the American College of Cardiology published results of the Phase III GadaCAD 1 and GadaCAD 2 clinical trials for Gadavist® (gadobutrol) in their September 29, 2020 issue. The publication includes data that supported the FDA approval of Gadavist to assess myocardial perfusion (stress, rest) and late gadolinium enhancement (LGE) in adult patients with known or suspected coronary artery disease (CAD). The Journal of the American College of Cardiolog

Click to view original post